Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)
NCT ID: NCT04946500
Last Updated: 2021-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2021-05-15
2021-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections
NCT02782078
Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection
NCT01757236
Treatment of Methicillin-sensitive Staphylococcus Aureus (MSSA)
NCT01500837
Clindamycin as Antimicrobial Treatment for Streptococcus Spp. PeRiprosthetic Infection
NCT07335627
Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital
NCT05239312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clindamycin and Rifampicin
Patients treated with Clindamycin and Rifampicin
No interventions assigned to this group
Clindamycin and Fluoroquinolone
Patients treated with Clindamycin and Fluoroquinolone
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Infection must be mono-microbial or multi-microbial with Staphylococcus spp sensitive to Clindamycin.
* Infection may be acute or chronic, nosocomial or community-acquired.
* Patient having received a curative treatment with Clindamycin.
Exclusion Criteria
* Patients with mono-microbial infections other than Staphylococcus, multi-microbial infections including other bacteria than Staphylococcus, suspected Osteoarticular Infection without microbial identification.
* Patients with clindamycin-resistant Staphylococcal PJI, constitutive MLSb phenotype.
* Patients having received suspensive treatment with Clindamycin.
* Patients treated with Clindamycin as last line of treatment for a duration of less than 14 days.
* Patients refusing to participate
* Patients under legal protection (guardianship, curatorship, ..)
18 Years
120 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Brest
Brest, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CISTA - 29BRC21.0123
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.